Genentech keeps up growth, cites broader Avastin use

07/12/2007 | Forbes

Genentech says its best-selling cancer drug continues to push the company's growth and shows future promise. It has begun Phase III testing on Avastin as a treatment for a specific form of lung cancer and as a second-line treatment for colon cancer. The biotech also is talking to the FDA about Avastin as a possible combined therapy for advanced kidney cancer.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC